Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.7852W HIGH $4.98
Volume
5.55 M
Value Traded
645.08 K
Short % Float
5.44%
+40.71%Week
+30.33%1 Month
+23.26%3 Month
-57.49%6 Month
-83.86%5 Year
-88.7%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
202.99 M
EPS (TTM)
-0.76
P/E Ratio
-
Ent. Value
-9.94 M
Total Shares
127.67 M
Float Shares
99.04 M
Insiders
22.42%
Institutions
57.98%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ADCT Catalyst Timeline
Dated clinical, regulatory and corporate events for ADC Therapeutics SA
Catalyst Timeline
Dated clinical, regulatory & corporate events for ADC Therapeutics SA
593Total events
19Upcoming
130Tier-1 (high impact)
2018 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Debt Royalty FinancingCorporate
Amendment No. 2 to HealthCare Royalty Purchase and Sale Agreement
●Pre BLA MeetingZYNLONTAApprovedFDA Meeting
Pre-sBLA meeting with FDA held
diffuse large B-cell lymphoma (DLBCL)source ↗
▲Enrollment CompleteZYNLONTAApprovedTrial
LOTIS-7 enrollment completed
relapsed/refractory DLBCLsource ↗
▲Enrollment CompleteZYNLONTAApprovedTrial
Enrollment completed in LOTIS-7 Phase 1b trial of ZYNLONTA plus glofitamab
relapsed or refractory diffuse large B-cell lymphomasource ↗
▲Topline ReadoutZYNLONTAApprovedClinical Data
Topline data from LOTIS-5 confirmatory trial of ZYNLONTA plus rituximab
relapsed or refractory diffuse large B-cell lymphomasource ↗
▲Primary Endpoint MetZYNLONTAApprovedClinical Data
PFS primary endpoint met with statistical significance
relapsed or refractory diffuse large B-cell lymphomasource ↗
▲Topline ReadoutZYNLONTAApprovedClinical Data
LOTIS-5 topline results announced
diffuse large B-cell lymphoma (DLBCL)source ↗
◆Topline ReadoutZYNLONTAApprovedClinical Data
LOTIS-5 topline results expected in Q2 2026
relapsed or refractory diffuse large B-cell lymphoma (DLBCL)source ↗
◆Timing GuidancePresentation
Cash runway expected to fund multiple catalysts into second half of 2026
▲First Patient DosedADCX-020Trial
First patient dosed in Phase 1 trial of ADCX-020
advanced solid tumorssource ↗
▲Management ChangeCorporate
Appointment of Paul Jackson as COO, Magali Gibou as Chief Regulatory & Quality Officer, and Simon Sturge as Independent Chairman
◆Oral PresentationPresentation
TD Cowen 46th Annual Health Care Conference corporate presentation
▲Debt Royalty FinancingCorporate
Amended HealthCare Royalty financing agreement reducing change of control payment
◆Oral PresentationPresentation
ADC Therapeutics presentation at 44th Annual J.P. Morgan Healthcare Conference
◆Enrollment CompleteZYNLONTAApprovedTrial
Complete enrollment of approximately 100 patients at selected dose expected
relapsed/refractory diffuse large B-cell lymphomasource ↗
◆Topline ReadoutZYNLONTAApprovedClinical Data
Top-line results from LOTIS-5 anticipated
relapsed/refractory diffuse large B-cell lymphomasource ↗
◆sBLA SubmissionZYNLONTAApprovedRegulatory Filing
Supplemental BLA submission to FDA for ZYNLONTA in combination with rituximab
relapsed or refractory diffuse large B-cell lymphomasource ↗
▼Safety Signal DisclosedZYNLONTAApprovedSafety
Safety signals from LOTIS-7 trial: adverse events and cytokine release syndrome in patients receiving ZYNLONTA plus glofitamab
relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL)source ↗
▲Oral PresentationZYNLONTAApprovedPresentation
Updated data from LOTIS-7 Phase 1b trial of ZYNLONTA in combination with glofitamab presented
relapsed/refractory diffuse large B-cell lymphomasource ↗
▲Topline ReadoutZYNLONTAApprovedClinical Data
Updated LOTIS-7 data: 89.8% ORR, 77.6% CR with manageable safety
relapsed/refractory diffuse large B-cell lymphomasource ↗
◆Interim AnalysisZYNLONTAApprovedTrial
LOTIS-5 expected to reach prespecified PFS events by end of 2025
relapsed or refractory DLBCLsource ↗
●IND Enabling CompletePreclinical
IND-enabling activities completed for PSMA-targeting ADC at end of 2025
prostate cancer (PSMA-targeting)source ↗
●Oral PresentationZYNLONTAApprovedPresentation
Updated data from Phase 2 IIT of ZYNLONTA plus rituximab in r/r follicular lymphoma presented at 22nd International Workshop on Non-Hodgkin Lymphoma
relapsed/refractory follicular lymphomasource ↗
▲Quarterly UpdateZYNLONTAApprovedCorporate
Preliminary Q4 2025 ZYNLONTA net product revenue of ~$22M
relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL)source ↗
Past FDA Catalysts and PDUFA Decisions
How ADCT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-06-30 | ZYNLONTA (loncastuximab tesirine-lpyl) | Phase 2 interim results | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C48 / 100
Pipeline Score
$136M
Pipeline Value
$80M
Commercial Value
Fair Value
Valuation Signal
3
Drugs Scored
1.8x
rNPV / MCap
Top 21%
Micro Cap(rank 139 of 658)
Percentile Rank
ADC Therapeutics SA carries a moderate pipeline score (48/100), with $543M risk-adjusted pipeline value, led by Loncastuximab tesirine in Waldenstrom Macroglobulinemia (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $79.6M x 1.0 = $80M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| ZYNLONTA | $77M | $70M | +9.8% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Loncastuximab tesirine ADCMarketedNCT04384484 | Relapsed Diffuse Large B-Cell Lymphoma | Phase 3 | ACTIVE NOT_RECRUITING | 440 | Jun 30, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every ADCT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ZYNLONTA Accelerated | relapsed or refractory DLBCL | Phase 1b | 2026-06-30 | overall response rate: 89.8%; complete response: 77.6%Read More | ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination TrialRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Zaki MohamedOfficer (Chief Medical Officer) | Grant/Award | 213,900 896,317 held | $0.00 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ADCT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Redmile Group, LLC | 0.8 % (-78.9 %) | 12.33 M | 11.53 M | -25.49% ( -3.94 M) |
ADCT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ADCT ranks across every disease it competes in
Competitive Position is a premium feature
See how ADCT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialADCT News
ADCT▲ +12%on this news
ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
ADC Therapeutics announced a comprehensive financial restructuring, including an $86.6 million private placement to improve its capital structure and extend its cash runway into 2029. The restructuring involves amending agreements with HealthCare Royalty and refinancing a senior secured loan. These initiatives aim to bolster shareholder value while preparing for upcoming clinical data presentations.
Read more →ADCTADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
ADC Therapeutics announced that CEO Ameet Mallik will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on September 11, 2026. The event will be webcast live, providing an opportunity for investors to engage with the company's updates. ADC Therapeutics is known for its innovative work in antibody drug conjugates, particularly with its product ZYNLONTA.
Read more →ADCT▼ -14.6%on this news
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
ADC Therapeutics reported a net product revenue of $18.6 million for Q2 2026, reflecting continued commercial momentum. The company is evaluating the regulatory path for ZYNLONTA following a pre-sBLA meeting with the FDA, which raised concerns about the LOTIS-5 trial data. Enrollment for the LOTIS-7 trial has been completed, and ADC Therapeutics anticipates growth starting in 2027.
Read more →ADCT▲ +5.6%on this news
ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
ADC Therapeutics has announced a conference call scheduled for August 13, 2026, to discuss its financial results for the second quarter of 2026. The call will provide operational updates and will be accessible via a live webcast. The company continues to focus on its innovative ADC portfolio, particularly ZYNLONTA, which has received regulatory approvals.
Read more →ADCTADC Therapeutics Announces New Employee Inducement Grant
ADC Therapeutics announced a grant of options to purchase 17,000 common shares to a new employee as an inducement for employment. This grant, approved by the Compensation Committee, aims to motivate the employee to contribute significantly to the company's success. The options will vest over four years, contingent on continued employment.
Read more →ADCTADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
ADC Therapeutics has completed enrollment in the LOTIS-7 Phase 1b trial, evaluating ZYNLONTA in combination with glofitamab for relapsed or refractory DLBCL. The trial included 100 patients, with results expected in late 2026. Preliminary data shows a high overall response rate, indicating strong potential for this treatment combination.
Read more →ADCT▼ -7%on this news
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
ADC Therapeutics has announced a strategic reorganization to support its ZYNLONTA franchise, which includes a planned 17% workforce reduction aimed at generating annual savings of around $10 million. The company is focused on key regulatory milestones, including a pre-sBLA meeting with the FDA and the completion of ongoing clinical trials. This restructuring is intended to enhance financial flexibility while maintaining support for ZYNLONTA's commercial activities.
Read more →ADCTADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics announced positive topline results from the LOTIS-5 Phase 3 trial of ZYNLONTA in combination with rituximab for relapsed or refractory diffuse large B-cell lymphoma. The trial met its primary endpoint of progression-free survival with statistical significance, while also showing improved complete response rates. However, the test arm exhibited higher rates of serious adverse events, particularly in older patients. The company plans to discuss these results with the FDA in preparation for a supplemental Biologics License Application.
Read more →ADCTADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
ADC Therapeutics reported a net product revenue of $20 million for Q1 2026, reflecting growth from the previous year. The company anticipates topline results from the LOTIS-5 Phase 3 trial in Q2 2026 and full data by year-end. Despite a significant net loss of $33 million, ADC maintains a robust cash position, projecting a runway into 2028.
Read more →ADCTADC Therapeutics Makes Grants to New Employees Under Inducement Plan ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
ADC Therapeutics announced the grant of stock options to two new employees as an inducement for their employment, totaling 49,400 shares. This decision was approved by the company’s Compensation Committee to motivate and reward performance under its Inducement Plan. By offering these grants, ADC Therapeutics aims to enhance its workforce capabilities and contribute to the company's overall success.
Read more →ADCTADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026
ADC Therapeutics announced a conference call scheduled for May 4, 2026, to discuss its first quarter financial results and operational updates. The call will be accessible via a toll-free number and a live webcast. The company is recognized for its advancements in antibody drug conjugates, particularly with ZYNLONTA, which has received FDA approval.
Read more →ADCTADC Therapeutics S.A. Investigated by the Portnoy Law Firm
ADC Therapeutics S.A. is under investigation by the Portnoy Law Firm for potential securities fraud related to its recent stock drop. This decline was precipitated by safety concerns regarding its oncology therapeutic development program. A significant decrease in stock price was linked to new data from the LOTIS-7 Phase 1b trial, where safety signals raised alarms about combination treatment risks. The firm is encouraging affected investors to discuss their legal options.
Read more →ADCTADC Contract Manufacturing Market Report 2026 (7th Edition) | Commercial Scale Dominates ADC Manufacturing with 90% Market Share | A Clear Analysis of Market Trends, Drivers, Challenges, and Opportunities
The ADC contract manufacturing market is projected to expand significantly, increasing from USD 2.13 billion to USD 3.21 billion by 2035, with a CAGR of 4.6%. The growing role of antibody drug conjugates (ADCs) in cancer treatments drives this expansion, particularly as many developers are outsourcing to contract manufacturers. The market is primarily dominated by the commercial scale, accounting for nearly 90% of the sector. North America is anticipated to see substantial growth, while Asia-Pacific regions also exhibit promising growth rates due to cost advantages.
Read more →ADCTAdcytherix Doses First Patient in Phase 1 Trial of ADCX-020 and Strengthens Leadership to Support Next Phase of Growth
Adcytherix announced the dosing of its first patient in a Phase 1 clinical trial of ADCX-020, marking its transition to a clinical-stage company. The trial aims to assess the safety and anti-tumor activity of ADCX-020 in patients with advanced solid tumors. Additionally, the company has reinforced its leadership team with significant appointments to support pipeline expansion and growth strategies. The successful dosing comes less than two years after the company's inception and follows a substantial financing round.
Read more →ADCT▲ +13.5%on this news
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported...
ADC Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting a net product revenue of approximately $73.6 million for the year. The company anticipates significant milestones in 2026 with topline data expected from the LOTIS-5 Phase 3 trial. Despite a net loss for the year, ADC has a strong cash position projected to support operations until at least 2028, allowing for continued investment in its ZYNLONTA clinical programs. A strategic amendment to its financing agreement was also noted, which may enhance future operational flexibility.
Read more →ADCTADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026
ADC Therapeutics will host a conference call on March 10, 2026, to discuss its financial results for Q4 and the full year of 2025. The call will provide operational updates and is accessible via a toll-free number and a live webcast. ADC Therapeutics continues to innovate in the field of antibody drug conjugates, particularly with its product ZYNLONTA.
Read more →ADCTADC Cytotoxic Payloads and Warheads Industry Research Report 2026-2035 - Breakthrough Cancer Therapies and Next-Generation ADC Innovations Accelerate Market Expansion
The ADC cytotoxic payloads and warheads market is projected to grow significantly, reaching USD 720.2 million by 2035 from USD 469.3 million today, driven by advancements in targeted cancer therapies. Innovations in linker and payload technologies are optimizing therapeutic efficacy, while increased investment supports market expansion. However, challenges such as the complexity of handling potent substances and high development costs may impede progress. Notably, Europe is expected to lead the market, thanks to strong collaborations and advanced manufacturing capabilities.
Read more →ADCTADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics has granted options to purchase 135,000 shares to three new employees as part of its Inducement Plan. This initiative aims to motivate and reward the new hires, ensuring their contributions to the company's success. The grants will vest over four years, contingent on continued employment.
Read more →ADCTADC Therapeutics to Participate in March Investor Conferences
ADC Therapeutics announced its participation in two upcoming investor conferences in March 2026. The events include the TD Cowen 46th Annual Health Care Conference and the Jefferies Biotech on the Beach Summit. CEO Ameet Mallik will present at the TD Cowen conference, highlighting the company's advancements in antibody drug conjugates, particularly ZYNLONTA.
Read more →About ADC Therapeutics SA
HeadquartersBIOPOLE, EPALINGES, V8, 1066
Founded2011
BIOPHARMAWATCH ELITE PLUS
Trade the next ADCT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime